Spyre Therapeutics, Inc. - Common Stock — キャッシュフロー (NASDAQ:SYRE) | MetaTrader

チャート全体を表示 Full chart

Financials

概要明細書統計

営業活動によるキャッシュフロー -75.78 M-53.72 M-80.14 M-99.91 M-157.41 M-169.25 M -185.63 M 投資活動によるキャッシュフロー -7.6 M-22.62 M57.01 M-108.39 M-353.29 M-143.47 M -86.83 M 財務活動によるキャッシュフロー 154.51 M1.39 M42.68 M361.08 M410.91 M309.02 M 321.15 M フリーキャッシュフロー -75.78 M-53.72 M-80.14 M-99.91 M-157.41 M-169.25 M -185.63 M

ニュース

SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?

Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis - Slideshow (NASDAQ:SYRE) 2026-04-14

Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Transcript

Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis Results

Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms (NASDAQ:SYRE)

Leerink、治験スケジュール前倒しでSpyre株のアウトパフォーム評価を維持

Leerink reiterates Spyre stock Outperform on faster trial timeline

Spyre Therapeuticsの株式、Guggenheimが2026年のトップピックとして維持

Spyre Therapeutics stock remains top 2026 pick at Guggenheim

Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript

3 ‘Strong Buy’ Stocks to Buy in Today’s Volatile Market, 2/23/2026, According to Top Analysts - TipRanks.com

Spyre Therapeuticsの株価が42.93ドルで52週高値を記録